# Risk Prediction of Dexmedetomidine-associated Hemodynamic Instability

> **NCT03285087** · PHASE2,PHASE3 · SUSPENDED · sponsor: **Assiut University** · enrollment: 250 (estimated)

## Conditions studied

- Sedation

## Interventions

- **DRUG:** DEX 0.2 μg/kg/h.

## Key facts

- **NCT ID:** NCT03285087
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-06
- **Primary completion:** 2022-08
- **Final completion:** 2022-08
- **Target enrollment:** 250 (ESTIMATED)
- **Why stopped:** dexmedetomidine is unavailable in this time
- **Last updated:** 2021-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03285087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03285087, "Risk Prediction of Dexmedetomidine-associated Hemodynamic Instability". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03285087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*